Stockreport

ArriVent BioPharma Reports Third Quarter 2024 Financial Results

ArriVent BioPharma, Inc.  (AVBP) 
PDF Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FUR [Read more]